We’re improving your experience!

×

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03485729
Title ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors Oncoceutics, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Rutgers, The State University of New Jersey New Brunswick New Jersey 08903 United States Details
UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27599 United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field